Replies to post #235228 on Biotech Values

[DewDiligence]

Re: GSK’s RSV vaccines in development

…this is going to be a long multi year phase 3 program but the payoff could be huge on par w Shingrix….

It’s notable that GSK’s pediatric RSV vaccine is a year or two behind the maternal RSV vaccine; perhaps if the maternal vaccine attains strong market penetration, the pediatric vaccine (which is mostly for infants) will become superfluous, commercially.

p.s. MRNA is also working on an RSV vaccine or vaccines.

p.p.s. GSK’s RSV vaccine for older adults (age 60-80) uses the same adjuvant as Shingrix.

[DewDiligence]

Update on GSK’s RSV vaccine for adults:

https://www.evaluate.com/vantage/articles/news/trial-results-snippets/outstanding-questions-overshadow-gsks-respiratory